These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25970793)

  • 1. Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine.
    Li C; Xu K; Hashem A; Shao M; Liu S; Zou Y; Gao Q; Zhang Y; Yuan L; Xu M; Li X; Wang J
    Hum Vaccin Immunother; 2015; 11(6):1351-6. PubMed ID: 25970793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.
    Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP
    Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and applications of universal H7 subtype-specific antibodies for the analysis of influenza H7N9 vaccines.
    Gravel C; Elmgren C; Muralidharan A; Hashem AM; Jaentschke B; Xu K; Widdison J; Arnold K; Farnsworth A; Rinfret A; Van Domselaar G; Wang J; Li C; Li X
    Vaccine; 2015 Feb; 33(9):1129-34. PubMed ID: 25620245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of recombinant hemagglutinin proteins as alternative antigen standards for pandemic influenza vaccines.
    Choi Y; Kwon SY; Oh HJ; Shim S; Chang S; Chung HJ; Kim DK; Park Y; Lee Y
    Biotechnol Lett; 2017 Sep; 39(9):1375-1380. PubMed ID: 28612264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the potency of a cell-based seasonal quadrivalent influenza vaccine using a purified primary liquid standard.
    Takahashi H; Fujimoto T; Horikoshi F; Uotani T; Okutani M; Shimasaki N; Hamamoto I; Odagiri T; Nobusawa E
    Biologicals; 2020 Nov; 68():32-39. PubMed ID: 33023810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency determination of inactivated H7 influenza vaccines using monoclonal antibody-based ELISA and biolayer interferometry assays.
    Vasudevan A; Woerner A; Schmeisser F; Verma S; Williams O; Weir JP
    Influenza Other Respir Viruses; 2018 Mar; 12(2):250-258. PubMed ID: 29152878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity.
    Wen Y; Palladino G; Xie Y; Ferrari A; Settembre EC
    Vaccine; 2018 May; 36(21):3010-3017. PubMed ID: 29680201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformationally selective biophysical assay for influenza vaccine potency determination.
    Wen Y; Han L; Palladino G; Ferrari A; Xie Y; Carfi A; Dormitzer PR; Settembre EC
    Vaccine; 2015 Oct; 33(41):5342-5349. PubMed ID: 26348403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China.
    Li C; Shao M; Cui X; Song Y; Li J; Yuan L; Fang H; Liang Z; Cyr TD; Li F; Li X; Wang J
    Biologicals; 2010 Mar; 38(2):284-9. PubMed ID: 20074976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.
    Khurana S; King LR; Manischewitz J; Coyle EM; Golding H
    Vaccine; 2014 Apr; 32(19):2188-97. PubMed ID: 24613520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reference antigen-free and antibody-free LTD-IDMS assay for influenza H7N9 vaccine in vitro potency determination.
    Morgenstern K; Xie Y; Palladino G; Barr JR; Settembre EC; Williams TL; Wen Y
    Vaccine; 2018 Oct; 36(41):6144-6151. PubMed ID: 30194004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of standard reagents for cell-based prepandemic influenza vaccine products.
    Lai CC; Weng TC; Chen PL; Tseng YF; Lin CY; Chia MY; Sung WC; Lee MS; Hu AY
    Hum Vaccin Immunother; 2020 Sep; 16(9):2245-2251. PubMed ID: 32118516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs.
    Ridenour C; Johnson A; Winne E; Hossain J; Mateu-Petit G; Balish A; Santana W; Kim T; Davis C; Cox NJ; Barr JR; Donis RO; Villanueva J; Williams TL; Chen LM
    Influenza Other Respir Viruses; 2015 Sep; 9(5):263-70. PubMed ID: 25962412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.
    Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP
    Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines.
    Kuck LR; Byrne-Nash R; Gillis J; Bueter K; Couzens LK; Eichelberger MC; Rowlen KL
    Vaccine; 2018 May; 36(21):2937-2945. PubMed ID: 29699789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the proficiency of single radial immunodiffusion assays for quality control of influenza vaccines in Korea.
    Choi Y; Lee S; Kwon SY; Lee Y; Park YK; Ban SJ
    Biologicals; 2017 Nov; 50():137-140. PubMed ID: 29111376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of deglycosylation to SDS PAGE analysis improves calibration of influenza antigen standards.
    Harvey R; Hamill M; Robertson JS; Minor PD; Vodeiko GM; Weir JP; Takahashi H; Harada Y; Itamura S; Bamford P; Dalla Pozza T; Engelhardt OG
    Biologicals; 2012 Jan; 40(1):96-9. PubMed ID: 22244521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The stability and immunogenicity of inactivated MDCK cell-derived influenza H7N9 viruses.
    Tzeng TT; Lai CC; Weng TC; Cyue MH; Tsai SY; Tseng YF; Sung WC; Lee MS; Hu AY
    Vaccine; 2019 Nov; 37(47):7117-7122. PubMed ID: 31383484
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    An Y; Parsons LM; Jankowska E; Melnyk D; Joshi M; Cipollo JF
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30355697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trypsin pre-treatment corrects SRID over-estimation of immunologically active, pre-fusion HA caused by mixed immunoprecipitin rings.
    Wen Y; Palladino G; Xie Y; Ferrari A; Ma X; Han L; Dormitzer PR; Settembre EC
    Vaccine; 2016 Jun; 34(29):3388-95. PubMed ID: 27154389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.